Rethinking dopamine D3 receptor pharmacology in Restless Legs Syndrome

Sleep · Published 2026-06-03 · DOI 10.1093/sleep/zsag156

Authors (1)

Maria Paola Mogavero

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mogavero, M. (2026). Rethinking dopamine D3 receptor pharmacology in Restless Legs Syndrome. Sleep. https://doi.org/10.1093/sleep/zsag156

Related articles

• On the Directionality of Predictor–Outcome Assignment When Modeling Polygenic Risk for Alzheimer's Disease Alongside Sleep Arousal Phenotypes · Sleep · 2026 · Same journal
• Dose-Response Associations Between Sleep Duration and Health Outcomes in Adults: Comparison Between Self-Reported and Device-Based Measures · Sleep · 2026 · Same journal
• Response to “On the Directionality of Predictor–Outcome Assignment When Modeling Polygenic Risk for Alzheimer's Disease Alongside Sleep Arousal Phenotypes” · Sleep · 2026 · Same journal
• Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses · Sleep · 2026 · Same journal
• Deltas’ and spindles’ cross-area synchronization and ripple subtypes · Sleep · 2026 · Same journal
• Religiosity and spirituality as stressors or stress relievers in relation to sleep health among African American women · Sleep · 2026 · Same journal
• Automated deep learning-based arousal detection complies with ten expert scorers in unseen data · Sleep · 2026 · Same journal
• Real-world effectiveness and safety of tonic motor activation therapy for refractory restless legs syndrome: 90-day outcomes from the THRIVE prospective observational study · Sleep · 2026 · Same journal
• Beyond Device Downloads: Residual Sleep Apnea and Hypoxemia Missed by Flow-Based CPAP Monitoring · Sleep · 2026 · Same journal
• Fear in Dreams Predicts Stronger Affect Reactivity in Wakefulness · Sleep · 2026 · Same journal